Dalton Signor

Dalton Signor has a diverse work experience in the medical technology industry. In 2019, they founded Miist Therapeutics, a company that develops an inhaled drug delivery platform with a personalized dosing system. Miist Therapeutics focuses on creating effective and personalized inhaled medicines and eliminating traditional manufacturing methods. Dalton is also the CEO of Miist Therapeutics and is currently working on developing an FDA approved pulmonary nicotine replacement therapy inhaler for smoking addiction treatment.

In 2022, Dalton joined ZeroTo510 - Medical Device Accelerator, a prominent US accelerator for medical technologies. Dalton is responsible for developing regulatory, reimbursement, and commercialization pathways for medical innovations. Additionally, Dalton is an investor in Miist Therapeutics.

Prior to their role at ZeroTo510, Dalton was a founder in the LD17 Cohort of Entrepreneur First, the world's leading talent investor. Dalton has funded over 500 tech startups with a portfolio valuation of $4 billion. Again, they were an investor in Miist Therapeutics.

In 2021, Dalton participated in the DuPont SCIENCE INC Accelerator, an accelerator for hard science, pharmaceutical, and medical device startups. The accelerator is a collaboration between the University of Delaware and DuPont. Once again, they were also an investor in Miist Therapeutics.

Overall, Dalton Signor has extensive experience in the medical technology industry, particularly in the development and commercialization of innovative medical devices.

Dalton Signor has pursued education in the field of Management Consulting at Villanova University. No specific start or end year has been mentioned, thus the duration of their education remains unknown.